NCT02111850: T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

NCT02111850
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MAGE-A3, HLA
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 70 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: Tumors must be HLA-DP0401/0402 positive and express the MAGE-A3-DP4 antigen
Exclusions: Patients with 4 or more symptomatic brain metastases that are more than 1 cm in diameter
https://ClinicalTrials.gov/show/NCT02111850

Comments are closed.

Up ↑